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Abstract
The role of umbilical cord blood transplantation (CBT) in acute myeloid leukemia (AML) patients with active disease at
allogeneic hematopoietic cell transplantation (allo-HCT) remains poorly investigated. In this study, we compared
transplantation outcomes of 2963 patients with primary refractory or relapsed AML given CBT, 10/10 HLA-matched
UD, or 9/10 HLA-matched UD allo-HCT from 2004 to 2015 at EBMT-afﬁliated centers. Neutrophil engraftment and
complete remission rates in CBT, UD 10/10, and UD 9/10 recipients were 75 and 48%, 93 and 69%, and 93 and 70%,
respectively. In multivariate Cox analyses, in comparison with CBT (n= 285), UD 10/10 recipients (n= 2001) had a
lower incidence of relapse (HR= 0.7, P= 0.001), a lower incidence of non relapse mortality (HR= 0.6, P < 0.001), better
GVHD-free and leukemia-free survival (GRFS, HR= 0.8, P < 0.001) and better survival (HR= 0.6, P < 0.001). Further, in
comparison with CBT, 9/10 UD recipients (n= 677) also had a lower incidence of relapse (HR= 0.8, P= 0.02), a lower
incidence of nonrelapse mortality (HR= 0.7, P= 0.008), better GRFS (HR= 0.8, P= 0.01) and better survival (HR= 0.7,
P < 0.001). In summary, these data suggest that in AML patients with active disease at transplantation, allo-HCT with
UD results in better transplantation outcomes than CBT.
Introduction
Allogeneic hematopoietic stem cell transplantation
(allo-HCT) has remained the only potentially curative
option for most patients with relapsed or primary
refractory acute myeloid leukemia (AML)1,2. This
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approach is thought to rely mostly on graft-versus-
leukemia (GvL) effects for tumor eradication3–5.
For adult patients with AML in complete remission
(CR) who lack a suitable human leukocyte antigen (HLA)-
identical sibling, and cord blood transplantation (CBT)
has proved to be an adequate alternative to HLA-matched
unrelated (UD) bone marrow (BM)/peripheral blood stem
cell (PBSC) transplantation6–8.
We recently compared GvL effects following low-
intensity non myeloablative conditioning regimen
according to donor type9. We observed that, in compar-
ison with patients given grafts from HLA-matched unre-
lated donor (UD 10/10), those receiving CBT had similar
overall survival (OS) but better GVHD-free and relapse-
free survival (GRFS). These results are in line with another
study from the Fred Hutchinson Cancer Research Center
that demonstrated that, among AML patients in CR but
with minimal residual disease at transplantation, those
receiving CBT had at least as good overall survival (OS)
than those given grafts from UD10/10, and better OS than
those receiving grafts from HLA-mismatched UD10.
We hypothesized that, since CBT provides better out-
come than UD in AML patients with minimal residual
disease at transplantation, transplantation outcomes
might be better with CBT than with UD in AML patients
with active disease at transplantation. In order to chal-
lenge this hypothesis, we performed a large registry study
comparing CBT with UD 10/10 or 1-antigen HLA-mis-
matched UD (UD 9/10) in patients with primary refrac-
tory or untreated/refractory relapsed AML.
Patients and Methods
Data collection
This is a retrospective, multicenter registry-based study
performed by the Acute Leukemia Working Party
(ALWP) of the European society for Blood and Marrow
Transplantation (EBMT) and by Eurocord. EBMT registry
is a voluntary working group of more than 500 transplant
centers, participants of which are required once a year to
report all consecutive stem cell transplantations and
follow-up. Audits are routinely performed to determine
the accuracy of the data. Eurocord collects data on CBT
performed in >50 countries worldwide and >500 trans-
plant centers, mainly EBMT centers.
Inclusion criteria were adult (≥18 years) patients, de
novo or secondary AML, primary refractory (deﬁned as
absence of CR (<5% marrow blasts) achievement after
induction chemotherapy1) or in ﬁrst or second relapse at
transplantation, transplantation between 2004 and 2015,
and either a 10/10 HLA-matched unrelated donor (UD
10/10), a 9/10 HLA-matched unrelated donor (UD 9/10),
or a single or double CBT. For UD, HLA-A, HLA-B,
HLA-C, HLA-DR, and HLA-DQ were typed at the allelic
level. For CBT, HLA-compatibility requirements followed
the current practice of antigen level typing for HLA-A and
HLA-B and allele level typing of HLA-DRB1. CB units
were 4–6/6 HLA-A, HLA-B, and HLA-DRB1 matched to
the recipient and to the other unit in case of double CBT
in most patients11,12. HLA disparities between each unit
and the recipient and between the two units were not
necessarily at the same loci. Grading of acute and chronic
GVHD was performed using established criteria13.
For the purpose of this study, all necessary data were
collected according to EBMT guidelines.
Ethics approval and consent to participate
The scientiﬁc boards of the ALWP of EBMT and of
Eurocord approved this study. Since 1990, patients have
provided informed consent authorizing the use of their
personal information for research purposes.
Statistical analyses
Data from all patients meeting the inclusion/exclusion
criteria were included in the analyses. Start time was date
of transplant for all endpoints. Neutrophil engraftment
was deﬁned as ﬁrst of 3 consecutive days with a neu-
trophil count of at least 0.5 × 109/L.
Cumulative incidence functions were used for relapse
incidence and non relapse mortality (NRM) in a com-
peting risk setting, since death and relapse were com-
peting together. For estimating the cumulative incidence
of engraftment and chronic GVHD, death was considered
as a competing event. Overall (OS) and leukemia-free
(LFS) survivals were estimated using the Kaplan-Meier
estimates. GVHD and relapse-free survival (GRFS) was
deﬁned as being alive with neither grade III-IV acute
GVHD, extensive chronic GVHD nor disease relapse14.
The main characteristics at diagnosis and at transplan-
tation were compared between CBT and 10/10 or 9/10
UD groups using Kruskall Walis tests for quantitative
variables, Chi-square test or Fisher exact test for catego-
rical variables. Univariate analyses were done using Gray’s
test for cumulative incidence function and log rank test
for OS and LFS.
Associations between donor type and transplantation
outcomes were evaluated in multivariable analyses, using
Cox proportional hazards. We used propensity scores (PS)
matching to control for pre-treatment imbalances on
observed variables. The following factors were included in
the propensity score model: age, year of transplant, status
at transplantation (primary refractory or relapse), diag-
nosis (de novo or secondary AML), sex matching (female
to male vs other), patient and donor CMV serology,
conditioning intensity (RIC or MAC). The estimation of
propensity score was performed using generalized boos-
ted models15. We weighted the 3 groups receiving either
CBT, 10/10, or 9/10 UD by estimating the Average
Treatment Effect (ATE). We checked the balance between
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the groups looking to ATE Weighted means. Then, we
used pairwise ATEs to ﬁt weighted KM and Cox models.
All tests were two sided. The type I error rate was ﬁxed at
0.05 for determination of factors associated with time to
event outcomes. Analyses were performed using the R
statistical software version 3.4.0. Propensity score analysis
was performed using the mnps function of the Twang
package (http://cran.rproject.org/web/packages/twang/




Data from 2963 patients with primary or secondary AML
were included in this study (Table 1). Two hundred eighty
ﬁve patients underwent a single (n= 175) or double (n=
110) CBT, 2001 an UD 10/10 and 677 an UD 9/10 allo-
HCT. In comparison to 10/10 UD or 9/10 UD recipients,
CBT patients were younger (48 vs. 55 and 55 years,
respectively, P < 0.001), were less frequently transplanted
with primary refractory disease (37% vs. 50 and 42%,
respectively, P= 0.009), and were more frequently condi-
tioned with a myeloablative regimen (52% vs. 46 and 42%,
respectively, P < 0.001). However, they received less fre-
quently in vivo T cell depleting agents such as ATG or
alemtuzumab (62% vs. 75 and 85%, respectively, P < 0.0001).
Engraftment and GVHD
Cumulative incidence of neutrophil engraftment at day
60 was 73%, 94 and 93% in CBT, UD 10/10 and UD 9/10,
respectively (P < 0.001). Cumulative incidence of grades








Median patient age, year
(range)
47 (18–71) 55 (18–77) 55 (18–77) <0.001
Median follow-up (pts
alive), month (range)
23 (2–121) 22 (1–146) 27 (1–136) <0.001
Median year of
transplantation
2009 2011 2011 <0.001
Recipient gender M, # (%) 139 (49) 1090 (55) 358 (53) 0.2
F donor to M recipient,
# (%)
61 (24) 226 (12) 113 (17) <0.001
Karnofsky performance status at Tx
<80 37 (15) 268 (14) 86 (13) 0.8
>=80 216 (85) 1611 (86) 555 (87)
Missing 32 122 36
Diagnosis, # (%)
De novo AML 204 (72) 1282 (64) 435 (64) 0.04
Secondary AML 81 (28) 719 (36) 242 (36)
Status at transplantation, # (%)
Primary refractory 106 (37) 999 (50) 286 (42) <0.001
First relapse 146 (50) 876 (44) 336 (50)
Second relapse 37 (13) 126 (6) 55 (8)
Cytogenetics, # (%)
Good riskb 8 (4) 56 (5) 23 (5) 0.001
Intermediate riskc 44 (25) 178 (15) 75 (18)
High riskd 46 (26) 201 (17) 85 (20)
Secondary AML 81 (45) 719 (62) 242 (57)
Not reported/failed 106 847 252
FLT3-ITD, # (%)
Negative 28 (58) 150 (61) 52 (52) 0.3
Positive 20 (42) 94 (39) 48 (48)
Missing 237 1757 577
Stem cell source
Bone marrow 152 (8) 56 (8)
Peripheral blood stem
cells
1849 (92) 620 (92)
Single CBT 175 (61)
Double CBT 110 (39)
Patient CMV seropositive,
# (%)
169 (69) 1222 (63) 430 (66) 0.1
Conditioning intensity, # (%)
Myeloablative (MAC) 148 (52) 901 (46) 276 (42) 0.009
Reduced-intensity (RIC) 135 (48) 1062 (54) 387 (58)
Conditioning regimen, # (%)
Cy-TBI 106 (39) 208 (11) 70 (11) <0.001
Flu-TBI 10 (4) 204 (10) 44 (7)
BuCy 13 (5) 207 (11) 60 (9)
BuFlu 6 (2) 323 (17) 98 (15)
FluMel 15 (5) 255 (13) 98 (15)
TBF 66 (24) 32 (2) 24 (4)
Flamsa TBI/chemo 23 (8) 454 (23) 184 (28)
Other 35 (13) 273 (14) 83 (12)
Missing 11 45 16
In vivo T-cell depletion, # (%)
Yes 98 (38) 485 (25) 101 (15) <0.001
No 159 (62) 1491 (75) 569 (85)









Postgrafting immunosuppression, # (%)
CSP alone 58 (23) 206 (11) 64 (10) <0.001
CSP (or tacro) + MTX
+/− MMF
13 (5) 686 (35) 220 (33)
CSP (or tacro) + MMF 174 (69) 966 (50) 345 (52)
Post-transplant
cyclophosphamide
7 (3) 28 (1) 13 (2)
Other 1 (0) 61 (3) 24 (4)
Missing 32 54 11
M male, CR complete remission, # number of patients, UD unrelated donor, CBT
cord blood transplantation, CSP cyclosporine, MMF mycophenolate mofetil,
FLT3-ITD FMS-related tyrosine kinase 3 internal tandem duplication, Cy
cyclophosphamide, TBI total body irradiation, Bu busulfan, Flu ﬂudarabine, Mel
Melphalan, TBF thiotepa + busulfan + ﬂudarabine, Flamsa ﬂudarabine +
amsacrine + cytarabine, MTX methotrexate
acalculated with χb statistics for categorical variables and Mann-Whitney test for
continuous variables
bdeﬁned as t(8;21), t(15;17), inv or del (16), or acute promyelocyticleukemia,
these abnormalities only or combined with others
cdeﬁned as all cytogenetics not belonging to the good or high risk (including
trisomias)
ddeﬁned as 11q23 abnormalities, complex caryotype, abnormalities of chromo-
somes 5 and 7
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II-IV acute GVHD were 27%, 30 and 36% in CBT, UD10/
10, and UD 9/10 recipients, respectively (P= 0.002). For
grade III-IV acute GVHD, the ﬁgures were 12%, 13 and
17%, respectively (P= 0.02). Further, the 2-year cumula-
tive incidences of chronic and extensive chronic GVHD
were lower in CBT patients (16 and 6%, respectively) than
in UD 10/10 (28 and 12%, respectively) or UD 9/10
patients (29 and 14%, respectively) (P < 0.001 and
P= 0.004, respectively).
CR achievement, relapse and NRM
Following transplantation, 69% of UD 10/10 recipients,
70% of 9/10 recipients versus 48% of CBT recipients
achieved a CR within 100 days (P < 0.001). Two-year
incidences of relapse and NRM were 43 and 26% in UD
10/10 recipients, 44 and 33% in UD 9/10 recipients and 47
and 38% in CBT recipients, respectively (Fig. 1). In mul-
tivariate Cox analyses, in comparison to CBT patients, UD
10/10 recipients had a lower incidence of relapse
(HR= 0.7, P= 0.001) and a lower incidence of NRM
(HR= 0.6, P < 0.001). Further, in comparison with CBT
patients UD 9/10 recipients had also a lower incidence of
relapse (HR= 0.8, P= 0.02) and a lower incidence of
NRM (HR= 0.7, P= 0.008).
Other factors associated with the relapse incidence in
multivariate analysis included secondary versus primary
AML (HR= 0.8, P= 0.01), relapsed versus primary
refractory AML (HR= 1.2, P= 0.02) and older age at
transplantation (HR per ten year= 0.9, P < 0.001). Fur-
ther, other factors associated with NRM in multivariate
analyses included older age (HR= 1.1, P < 0.001), female
donor to male recipient (HR= 1.2, P= 0.05) and patient
CMV seropositivity (HR= 1.3, P= 0.002).
OS, LFS, GRFS
At 2-year, OS, LFS, and GRFS were 37, 31, and 20% in
UD 10/10 recipients, 27, 23, and 16% in UD 9/10 reci-
pients, and 18, 16 and 11% in CBT patients, respectively.
In multivariate Cox analyses, in comparison with CBT,
UD 10/10 recipients had a better LFS (HR= 0.6, P <
0.001), a better GRFS (HR= 0.8, P < 0.001) and a better
OS (HR= 0.6, P < 0.001) (Table 2). Further, in compar-
ison to CBT patients, UD 9/10 recipients had also a better
LFS (HR= 0.7, P < 0.001), a better GRFS (HR= 0.8, P=
0.01) and a better OS (HR= 0.7, P < 0.001) (Table 2).
Other factors associated with transplantation outcomes
in multivariate analyses included relapsed versus primary
refractory AML that predicted poor LFS (HR= 1.1, P=
0.02) and OS (HR= 1.1, P= 0.04), while patient CMV
seropositivity predicted for poor LFS (HR= 1.2, P=
0.003), OS (HR= 1.2, P= 0.003), and GRFS (HR= 1.1,
P= 0.01).
Among CBT recipients, 38% of patients died because of
the original disease, 24% because of an infection, and 5%
because of GVHD. Among UD 10/10 recipients the ﬁg-
ures were 31, 13, and 7% respectively. Finally, among 9/10
recipients, the ﬁgures were 34, 15, and 13%, respectively.
Propensity score analysis
Given the differences in the study population between
the 3 groups we also performed analyses weighted with
propensity score. These analyses showed that in com-
parison with CBT recipients, UD 10/10 patients had lower
incidences of relapse and of nonrelapse mortality trans-
lating to better LFS, OS, and GRFS (Table 3). Further, in
comparison with CBT recipients, UD 9/10 patients had a
lower incidence of relapse, a not signiﬁcantly different
incidence of NRM, as well as better LFS, OS, and GRFS
(Table 3).
Discussion
Based on recent data demonstrating that in patients
with MRD at transplantation, CBT did as least as good as
UD transplantation, we performed a survey comparing
the outcomes of patients with refractory/relapsed AML
transplanted with a UD vs. a CB; several observations
were made.
First, we observed a high incidence of primary graft
failure, as well as a low incidence of CR achievement in
CBT recipients. The high incidence of graft failure in CBT
recipient was due in a large part to early AML progression
precluding neutrophil engraftment since only 49% of CBT
recipients achieved a CR after transplantation. This sug-
gests that the kinetic of GvL effects is slower in CBT than
in UD recipients. This might be due to the lower number
of T cells infused with CBT, as well as to their mostly
immature status16.
Second, we observed a signiﬁcantly higher NRM in CBT
patients than in UD recipients. While this could probably
be attributed in a part to the slow neutrophil engraftment
associated with CBT, it could also be due to delayed
immune reconstitution in CBT patients since the higher
non relapse mortality in CBT than in UD recipients was
due to infections. One cannot include that the large use of
ATG among CBT recipients was in part the cause of this
high infection-related mortality among CBT recipients17.
Recent advances in the ﬁeld of CBT engineering are likely
to improve the safety of CBT in AML patients with active
disease at transplantation18–20.
Consequently to the high disease-related and infection-
related mortality among CBT recipients, OS, LFS, and
GRFS were signiﬁcantly better both in UD 10/10 and in
UD 9/10 recipients than in CBT patients. These results
are in contrast with those observed in AML patients in CR
with or without MRD, where CBT did at least as good as
UD allo-HCT8–10.
There are some limitations in our study. They include
the heterogeneity in patients characteristics between the
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Fig. 1 Impact of donor type on transplantation outcomes. a Chronic GVHD. b Relapse. c Non relapse mortality. d LFS. e OS. f GRFS
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different groups and the lack of relevant data in the
database such as blast counts at transplantation, comor-
bidity score, or donor T cell reconstitution after allo-
HCT. We tried to address the heterogeneity question by
comparing transplantation outcomes between the three
different groups by using both multivariate Cox models
and propensity weighted Cox models.
In summary, these data suggest that in AML patients
with active disease at transplantation, allo-HCT with UD
results in better transplantation outcomes than CBT.
List of institutions
The EBMT registry is a voluntary working group of
more than 500 transplant centers, participants of which
are required once a year to report all consecutive stem cell
transplantations and follow-up. The list of institutions
reporting data included in this study is provided in the
supplemental data.
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Table 2 Impact of donor types on transplantation
outcomes in multivariate Cox models
HR 95% CI P
Relapse
CBT 1 – –
UD 10/10 0.7 0.6–0.9 <0.001
UD 9/10 0.8 0.6–1.0 0.02
Non relapse mortality
CBT 1 – –
UD 10/10 0.6 0.4–0.7 <0.001
UD 9/10 0.7 0.5–0.9 0.007
Leukemia-free survival
CBT 1 – –
UD 10/10 0.6 0.6–0.8 <0.001
UD 9/10 0.7 0.6–0.9 <0.001
Overall survival
CBT 1 – –
UD 10/10 0.6 0.5–0.7 <0.001
UD 9/10 0.7 0.6–0.9 0.001
GVHD-free and relapse-free survival
CBT 1 – –
UD 10/10 0.8 0.7–0.9 <0.001
UD 9/10 0.8 0.7–1.0 0.01
Table 3 Impact of donor types on transplantation
outcomes using Cox models weighted on propensity score
HR 95% CI P
Relapse
CBT 1 – –
UD 10/10 0.7 0.5–0.8 <0.001
UD 9/10 0.87 0.5–0.9 0.005
Non relapse mortality
CBT 1 – –
UD 10/10 0.6 0.5–0.8 <0.001
UD 9/10 0.8 0.6–1.1 0.1
Leukemia-free survival
CBT 1 – –
UD 10/10 0.6 0.5–0.8 <0.001
UD 9/10 0.7 0.6–0.9 0.002
Overall survival
CBT 1 – –
UD 10/10 0.6 0.5–0.8 <0.001
UD 9/10 0.8 0.6–0.9 0.004
GVHD-free and relapse-free survival
CBT 1 – –
UD 10/10 0.7 0.6–0.9 <0.001
UD 9/10 0.8 0.6–0.9 0.008
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